Marius Hoeper, MD, offers expert perspectives on the recently FDA-approved sotatercept, focusing on its mechanism of action, potential cost implications, and potential advantages and disadvantages it could offer compared with existing foundational therapies.
Video content above is prompted by the following question(s):
Family Key to PAH Care for Women, but Gaps Remain
June 18th 2025This study highlights the vital role of caregivers in supporting women living with pulmonary arterial hypertension (PAH) and underscores the need to enhance caregiver support and address unmet needs to improve patient outcomes.
Read More
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More